{Reference Type}: Clinical Trial, Phase I
{Title}: Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
{Author}: Brunner AM;Esteve J;Porkka K;Knapper S;Traer E;Scholl S;Garcia-Manero G;Vey N;Wermke M;Janssen JJWM;Narayan R;Fleming S;Loo S;Tovar N;Kontro M;Ottmann OG;Naidu P;Sun H;Han M;White R;Zhang N;Mohammed A;Sabatos-Peyton CA;Steensma DP;Rinne ML;Borate UM;Wei AH;
{Journal}: Am J Hematol
{Volume}: 99
{Issue}: 2
{Year}: 2024 02 22
{Factor}: 13.265
{DOI}: 10.1002/ajh.27161
{Abstract}: The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.